ADIM
NGVT icon

Alpha DNA Investment Management’s Ingevity NGVT Stock Holding History

Alpha DNA Investment Management’s Portfolio NGVT Stock Details NGVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$7K – 443
2021
Q1 		$7K Hold
100
– – 0.01% 319
2020
Q4 		$7K Buy
+100
New +$6.51K 0.01% 335

Other funds holding NGVT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BBCM
Broad Bay Capital Management New York $1.18B AUM 65.45% 1-Year Est. Return
AAM
Ardevora Asset Management London, United Kingdom $1.12B AUM 26.09% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alpha DNA Investment Management's NGVT Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Ingevity (NGVT) in Q2 2021, closing a stake of 100 shares — an estimated $7K sold.

Alpha DNA Investment Management first reported a position in NGVT in Q4 2020 and held it in 2 quarters. The position peaked at $7K in Q1 2021. 277 funds tracked by Wall St. Rank hold NGVT as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Ingevity position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 100 Ingevity shares in Q2 2021, an estimated $7K.
  • Alpha DNA Investment Management first reported a position in Ingevity in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Ingevity position peaked at $7K in Q1 2021.
  • 277 funds tracked by Wall St. Rank held Ingevity as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.